Ironwood Pharmaceuticals, Inc.
IRWD Healthcare Drug Manufacturers Specialty & Generic
Ironwood Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $296.2 million, down 15.7% from fiscal 2024. In the quarter to June 2026, revenue grew 32.6%, EPS grew 106.7%, free cash flow grew 486.7% and total debt was flat, each against the same quarter a year earlier.
Follow IRWD
Ironwood Pharmaceuticals, Inc. (IRWD) P/E ratio
As of 16 October 2026, Ironwood Pharmaceuticals, Inc. (IRWD) trades at a P/E ratio of 4.4×. Over the past ten years it has ranged from 0.0× (September 2025) to 129× (July 2024); the current reading is higher than 70% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of 19.2× and below the Healthcare sector median of 23.0×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 21.4× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 10.8× | 200.93% |
| FY2021 | 3.6× | (78.96%) |
| FY2020 | 17.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 5.3× | (4.12%) |
| Mar 2026 | 5.5× | (74.26%) |
| Dec 2025 | 21.4× | 201.16% |
| Sep 2025 | 7.1× | — |
| 42 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| EBS Emergent Biosolutions Inc. compare | n/m |
| TKNO Alpha Teknova, Inc. compare | n/m |
| AQST Aquestive Therapeutics, Inc. compare | n/m |
| EVO Evotec AG compare | n/m |
| TLRY Tilray Brands, Inc. compare | n/m |
| EOLS Evolus, Inc. compare | n/m |
| IRWD Ironwood Pharmaceuticals, Inc. | 4.4× |
| COLL Collegium Pharmaceutical, Inc. compare | 15.2× |
| KMDA Kamada Ltd. compare | 20.4× |
| Drug Manufacturers Specialty & Generic industry median | 19.2× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)